Nicholas C. Turner, MD, PhD, on INAVO120: Final Overall Survival Analysis
2025 ASCO Annual Meeting
Nicholas C. Turner, MD, PhD, of the Royal Marsden Hospital, presents final overall survival data from the INAVO120 trial of inavolisib/placebo plus palbociclib and fulvestrant in patients with PIK3CA-mutated, HR-positive, HER2-negative, endocrine-resistant advanced breast cancer (Abstract 1003).
Transcript
Disclaimer: This video transcript has not been proofread or edited and may contain errors.
Here at ASCO, we're presenting the overall survival results of the ANAVO-120 trial. This is a trial for patients with metastatic hormone receptor-positive, HER2-negative breast cancer that has got PIK3CA mutations and specifically for patients that are relapsing on endocrine therapy. We know that this is an aggressive type of breast cancer and we're very much in need of new therapies. And so the ANAVO-120 trial randomized these patients in the first-line setting to the standard of care, which was fulvestrant and palbociclib, or the addition of the PI3 kinase inhibitor inavolisib in the triplet. Inavolisib is a novel PI3 kinase inhibitor. It inhibits PIK3CA alpha, but also it degrades the alpha mutant protein and that probably improves the therapeutic window with inavolisib compared to other PI3 kinase inhibitors. And very importantly, inavolisib is combinable with fulvestrant and palbociclib at the maximum single agent doses. And so what we're doing in that triple combination is we're targeting the estrogen receptor, CDK4/6, and the PI3 kinase inhibitor. And by targeting all of these three key aspects of this type of breast cancer, we're really starting to get really significant efficacy. So in the primary readout of ANAVO-120, we demonstrated that adding in inavolisib substantially improved progression-free survival. And now with longer follow-up, we're also demonstrating that adding in inavolisib improved overall survival with a hazard ratio of 0.67, passing the statistical significance barrier. So that's improving overall survival by 33% on average. A median improvement is 7 months. But we also can look at some other really important endpoints in the study, in particular time to first use of chemotherapy. I mean, this is an endpoint that is very important for people, and the addition of inavolisib delayed the time to chemotherapy on average by almost two years. Now why are we seeing such a big improvement in the study? Partly it's that first-line efficacy substantially improving PFS by over half, as well as a substantial improvement in the response rate. And that of course carries through to delaying time to chemotherapy, but also because we're seeing such a reduction in tumor burden with the triplet that also enabled people in the second line to avoid chemotherapy more often. And it's all translated through to that almost doubling in time to chemotherapy. So this is potentially a really important new treatment option for these patients who've relapsed on endocrine therapy with PIK3CA mutant breast cancer.
Related Videos
The ASCO Post Staff
Manmeet Singh Ahluwalia, MD, MBA, FASCO, of Miami Cancer Institute, Baptist Health South Florida, discusses the ongoing LIBERATE trial, which is evaluating safety and technical efficacy of transcranial MR-guided microbubble-enhanced transcranial focused ultrasound for increasing blood circulating tumor and cell-free DNA levels in adults with glioblastoma (Abstract TPS2094).
The ASCO Post Staff
Luis G. Paz-Ares, MD, PhD, of Hospital Universitario 12 de Octubre, H12O-CNIO Lung Cancer Unit, Universidad Complutense and Ciberonc, discusses data from the TIGOS trial, a phase III study comparing the first-line use of atigotatug (an antifucosyl-GM1 monoclonal antibody) plus nivolumab fixed-dose combination with chemotherapy vs atezolizumab with chemotherapy in patients with extensive-stage small cell lung cancer (SCLC) (Abstract TPS8127).
The ASCO Post Staff
Clifford A. Hudis, MD, FASCO, FACP, Chief Executive Officer of ASCO, discusses ASCO Guidelines Assistant, an AI-based collaboration between ASCO and Google Cloud which draws from ASCO’s evidence-based, published clinical practice guidelines, offering clinicians ready access to timely, trustworthy information.
The ASCO Post Staff
Bjorn Henning Gronberg, MD, PhD, of Norwegian University of Science and Technology (NTNU) and St. Olavs Hospital, presents phase II findings on the efficacy of atezolizumab after chemoradiotherapy (CRT) in limited-stage small cell lung cancer (SCLC) (LBA8005).
The ASCO Post Staff
Luis G. Paz-Ares, MD, PhD, of Hospital Universitario 12 de Octubre, H12O-CNIO Lung Cancer Unit, Universidad Complutense and Ciberonc, presents primary results from the phase III IMforte trial, which evaluated lurbinectedin plus atezolizumab as first-line maintenance treatment in patients with extensive-stage small cell lung cancer (SCLC) (Abstract 8006).